Targeting SHP2 increases expression of PD-L1 and human leukocyte antigen (HLA) ABC in prostate cancer cells by phosphorylating STAT1, which is relevant to immune-cell interaction and immunotherapy tactics (145). The gene discussed is PTPN11; the disease is Familial prostate cancer.